Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Anemia 30Neoplasms 16Lung Neoplasms 3Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Pleural Effusion 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Genital Neoplasms, Female 1Fatigue 1Carcinoma 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × Darbepoetin alfa × Clear all
NCT00121030 2007-12-24

Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy

Amgen

Phase 2 Completed
Classical hematologyGynecologic

Anemia, Genital Neoplasms, Female, Ovarian Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡